Why the study?
Meds-to-beds programs support care transitions by providing medications and counseling before hospital discharge, but a comprehensive synthesis of their study designs, intervention elements, and outcomes was needed.
Current literature on Meds-to-Beds programs consists mostly of noncontrolled studies focused on healthcare utilization and costs, indicating a need for more rigorous studies on patient clinical outcomes.
Answers are grounded in this paper and cite their sources.
Meds-to-Beds evidence is mostly noncontrolled and utilization-focused; leaves open clinical outcome effects and requires RCTs.
PURPOSE: Meds-to-beds (MTB) programs support care transitions by providing medications and related counseling to patients before hospital discharge. This review describes studies of MTB programs in terms of their study designs, intervention elements, and outcomes. . METHODS: A rapid scoping review was performed searching MEDLINE, Embase, Web of Science, CINAHL, and International Pharmaceutical Abstracts (from inception to December 2023) for studies examining the implementation and evaluation of an MTB program. Citations and full-text articles were independently screened by 2 reviewers. An adaptation of the Consolidated Framework for Implementation Research for care transitions guided data extraction. Data were synthesized using the 3-stage approach of Petticrew and Roberts. . RESULTS: Titles and abstracts from 4,362 identified citations and 129 full-text articles were screened, with 45 studies extracted. Of these, quality improvement initiatives (n = 16; 36%) and retrospective cohort studies (n = 12; 27%) were the most common. The majority of included studies were published between 2019 and 2023 (n = 27; 60%) and were conducted in the US (n = 37; 82%). Twenty-nine studies (64%) examined an MTB program as the sole intervention, while 16 studies (36%) examined an MTB program as part of a complex intervention. More than half the studies examined multiple outcomes (n = 25; 56%), with the most studied outcomes being healthcare utilization or system outcomes (n = 32; 71%), cost effects or pharmacy operational impacts (n = 21; 47%), patient and caregiver experience (n = 11; 24%), and patient clinical outcomes (n = 7; 16%). CONCLUSION: This rapid scoping review highlights existing gaps in the literature around MTB programs. The reviewed studies primarily had noncontrolled study designs, focusing on healthcare utilization and cost or pharmacy operational impacts. Fewer studies examined patient and caregiver experiences and patient clinical outcomes. Future research expanding the breadth of outcomes studied using controlled designs is warranted. .
No takes yet. Share an insight, caveat, or question.
Muir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: